Rubicon Research has expanded its global footprint with the acquisition of a manufacturing facility in the United States for an enterprise value of USD 2.9 million. The company’s wholly owned subsidiary, AdvaGen Holdings, purchased the site in East Brunswick, New Jersey, from InvaTech Pharma Solutions, LLC. This strategic move establishes a US manufacturing base comparable in size to Rubicon’s existing facility in Satara, strengthening its supply chain resilience and proximity to customers.

The acquisition was completed on July 21, 2026, following a court-supervised competitive bid process under Section 363 of the U.S. Bankruptcy Code. As part of the transaction, AdvaGen Holdings has assumed the facility's lease and taken possession of all associated equipment, records, and permits. The site does not include any product approvals or filings.

The operational facility specializes in manufacturing oral solid and oral liquid formulations. It has maintained a USFDA inspection record for over a decade, marked by three successful inspections. The USFDA conducted an unannounced inspection in May 2026, resulting in a Form 483 with six observations. The company stated these observations were procedural and unrelated to data integrity, adding that corrective actions have been completed to facilitate a timely conclusion.

Looking ahead, the site will focus on producing specialty and high-value products, catering to demand from US government departments. Rubicon Research plans to commence manufacturing at the facility in calendar year 2027, pending the implementation of its quality management systems. Parag Sancheti, CEO of Rubicon Research, highlighted that the acquisition complements the company's growing portfolio and enhances agility in its global supply chain.

Rubicon Research has disclosed that the United States Food and Drug Administration (USFDA) conducted an unannounced inspection of its manufacturing facility located in Pithampur. The inspection took place from June 29 to July 3, 2026, spanning five days in total.

Inspection Outcome

Upon completion of the inspection, the USFDA issued a Form 483 to the company. The key details of the inspection outcome are summarised below:

Key Highlights

The following points summarise the critical aspects of the USFDA inspection:

• The inspection was conducted without prior notice, reflecting a standard unannounced regulatory audit procedure.
• The USFDA issued Form 483 at the close of the inspection, which is a standard document used to record observations noted by investigators.
• A total of 2 observations were recorded in the Form 483.
• No data integrity issues were identified during the inspection, which is a significant aspect of the regulatory outcome.

Form 483 is a formal document issued by the USFDA when investigators observe conditions that may constitute violations of regulations administered by the agency. The absence of data integrity findings is generally considered a notable aspect of any pharmaceutical facility inspection outcome.